World Generic Medicines Congress Americas 2010

Day One Wednesday 17th November 2010

8.00 Registration opens

GENERIC INDUSTRY HEALTH CHECK

9.00 Opening remarks from the Chair

9.15 The many facets of the global generics market: learning how best to balance access, affordability and innovation
Heather Bresch, President, Mylan
 
9.45 Financial forecast: economic analysis of the generic industry
Buddy Gumina, Co-Head Global Healthcare, Apax Partners

10.15 Speed Networking followed by morning refreshmentsHEALTH POLICY ENVIRONMENT

11.00 New U.S. health care law: impact on generics
Lori Neal Bowman, Director, Federal Government Affairs, Hospira

11.30 Congressional update and Q&A session on Hatch-Waxman Reform
The Honorable Henry Waxman, Member of Congress, The United States of America12.00 Federal Trade Commission: update on actions affecting the generic industryCommissioner Thomas Rosch, Federal Trade Commission

12.30 Lunch

BIOSIMILAR STRATEGY

1.30 The age of biosimilars: opportunities and challenges
Ameet Mallik, Global Business Unit Head Biopharmaceuticals, Sandoz

2.00 The US regulatory and policy environment for similar biotherapeutic products
Earl Dye, Director Technical Regulatory Policy & Strategy, Genentech

2.30 Commercial challenges of launching Biosimilars in UK
Pascal Brenneisen, CEO, Sandoz UK

3.00 Afternoon refreshments

3.30 Design, development and delivery of biologics for a global market
Crawford Brown, CEO, Eden Biodesign Ltd 

4.00 Biosimilar R&D and manufacturing strategies for commercial success
Cole Pinnow, Vice President of Global Specialty Pharmaceuticals, Hospira

4.30 Biosimilars: whether to play, where to play, and how to win
Markus Hauser, Associate Director for International Commercial Operations, Biogen Idec

5.00 Evening drinks reception Join your colleagues for a relaxed drink after the busy conference day.

Day Two Thursday 18th November 2010

9.00 Opening remarks from the Chair

GENERIC MEDICINES INDUSTRY LANDSCAPEINES INDUSTRY LANDSCAPE

9.10 Generic medicines: rethinking the future
Robert Wessman, Executive Chairman, Alvogen

9.40 Legal insight: ensuring access, management and protection of IP, as business models and markets evolve
Meg Snowden, Vice President Intellectual Property, Impax Laboratories

10.10 Morning refreshmentsINTERNATIONAL MARKET FOCUS

10.40 Future drivers for the generic pharma industry in Africa’s largest economy
Skhumbuzo Ngozwana, Deputy Chief Executive Officer, Cipla Medpro

11.10 The role of regional companies in the emerging MENA markets
Samih Darwazah, Non-Executive Chairman, Hikma Pharmaceuticals

11.40 China’s pharma industry: next 10 years of golden development opportunity
Dr Haucheng Wei, Chairman of the Board, Beijing Pharmaceutical Groups Holding / Beijing Double Crane Pharmaceutical Co.

12.10 Lunch

13.10 Perspective from an active supplier of generic APIs on the global market based in CEE
Theodore Iliopoulos, Vice President Operations, Polpharma Group

13.40 Market review: generic medicines in Canada
Agnes Klein, Director, Centre for Evaluation of Radioharmaceuticals and Biotherapeutics Biologics and Genetic Therapies Directorate, Health CanadaURE STRATEGIES

2.10 Enlightened Capitalism in the context of pharmaceuticals and health care delivery
Vikash Salig, CEO, Dr Reddy’s South Africa

2.40 What are the key challenges facing the generics in today’s global environment?
Dr Brian E. Harvey, Vice President U.S. Regulatory Policy, Global industry Regulatory Affairs, Sanofi-Aventis
Samih Darwazah, Non-Executive Chairman, Hikma Pharmaceuticals
Skhumbuzo Ngozwana, Deputy Chief Executive Officer, Cipla Medpro
Pascal Brenneisen, CEO, Sandoz UK

3.10 Afternoon refreshments

3.40 Lifecycle management, extending lifecycles and portfolio growth
Eric Mittleberg, Vice President, Product Development, Sandoz

4.10 Life cycle management for existing pharmaceuticals for innovator and generics
Salah Ahmed, President and CEO, Abon Pharmaceuticals

4.40 Close of conference and afternoon refreshments